BioMarin is a global biotechnology company that develops and commercialises innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The Shanbally facility opened in 2011 and employs over 350 people. In 2017 BioMarin completed an expanded warehouse, new administration and utilities offices, a canteen and conference facilities at Shanbally, while 2018 saw the completion of a Waste Water Pre-treatment Plant at the site and a new Bio-Assay Laboratory is currently being commissioned.
In September 2018 BioMarin announced that it is investing in a new Drug Product Filling Project at it’s Co. Cork facility. This project will allow the company to maximise the flexibility of the site with the expansion of the operational manufacturing capacity to meet the rise in the global demand for its therapies to treat rare genetic diseases that mostly affect children.
BioMarin, a drug group that focuses on treating patients with rare genetic disorders, many of them affecting children, opens a new Dublin headquarters for the EMEA region on Wednesday in a move that doubles the numbers employed.